Special Issue

Glycans and Glycan-Binding Proteins in Drug Research

Message from the Guest Editors

Glycans are a large and diverse family of biomolecules that contain a huge amount of molecular information that is decoded by lectins through specific carbohydrate-protein interactions. Due to the ubiquitous presence of these molecules in all organisms. carbohydrates are involved in a plethora of biological events, being key players in several pathological and physiological processes, including inflammation, cancer progression and metastases, cell development and differentiation, viral infection, etc. For this reason, carbohydrates and their derivatives are excellent building blocks to create drugs and biotools. The development of specific synthetic strategies and the analytical tools to prepare and characterize well-defined glycan structures have allowed for a deep understanding of their role to be developed, in turn leading to the advancement of this field. This Special Issue aims to collect new contributions in the field. focused on drug development based on glycans, which highlights the relevance of these molecules and the interest that they generate within the scientific community.

Guest Editors

Dr. Francisco Javier Rojo

Glycosystems Laboratory, Instituto de Investigaciones Químicas (IIQ), CSIC—Universidad de Sevilla, Av. Américo Vespucio 49, 41092 Seville, Spain

Dr. Javier Ramos-Soriano

Glycosystems Laboratory, Instituto de Investigaciones Químicas (IIQ), CSIC—Universidad de Sevilla, Av. Américo Vespucio 49, 41092 Seville, Spain

Deadline for manuscript submissions

closed (28 June 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/186488

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

